These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 31135513)

  • 1. Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease.
    Jaafar RF; Hajj Ali AM; Zaghal AM; Kanso M; Habib SG; Halaoui AF; Daniel F; Mokaddem F; Khalife MJ; Mukherji DM; Faraj WG
    Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1540-1544. PubMed ID: 31135513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.
    Kwok R; Choi KC; Wong GL; Zhang Y; Chan HL; Luk AO; Shu SS; Chan AW; Yeung MW; Chan JC; Kong AP; Wong VW
    Gut; 2016 Aug; 65(8):1359-68. PubMed ID: 25873639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of FibroMeter™ NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Aykut UE; Akyuz U; Yesil A; Eren F; Gerin F; Ergelen R; Celikel CA; Yilmaz Y
    Scand J Gastroenterol; 2014 Nov; 49(11):1343-8. PubMed ID: 25259621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.
    Cassinotto C; Boursier J; de Lédinghen V; Lebigot J; Lapuyade B; Cales P; Hiriart JB; Michalak S; Bail BL; Cartier V; Mouries A; Oberti F; Fouchard-Hubert I; Vergniol J; Aubé C
    Hepatology; 2016 Jun; 63(6):1817-27. PubMed ID: 26659452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease.
    Li Q; Huang C; Xu W; Hu Q; Chen L
    Medicine (Baltimore); 2020 Jun; 99(23):e20616. PubMed ID: 32502037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
    Parikh P; Patel J; Ingle M; Sawant P
    Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The relationship between diabetes mellitus and non-alcoholic fatty liver disease: a clinical and instrumental paired study].
    Sasunova AN; Goncharov AА; Gapparova KM; Isakov VA
    Ter Arkh; 2024 Sep; 96(8):764-770. PubMed ID: 39404721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of liver stiffness in non-alcoholic fatty liver disease with higher fibrosis-4 index than low cut-off index.
    Tomeno W; Imajo K; Kuwada Y; Ogawa Y; Kikuchi M; Honda Y; Kato T; Kessoku T; Kirikoshi H; Yoneda M; Kitahora T; Saito S; Ozawa Y; Nakajima A
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1411-1416. PubMed ID: 30506860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis.
    Sporea I; Mare R; Lupușoru R; Sima A; Sirli R; Popescu A; Timar R
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):167-74. PubMed ID: 27308647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease].
    Livzan MA; Akhmedov VA; Krolevets TS; Gaus OV; Cherkaschenko NA
    Ter Arkh; 2016; 88(12):62-68. PubMed ID: 28139562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients.
    Singh A; Le P; Peerzada MM; Lopez R; Alkhouri N
    J Clin Gastroenterol; 2018 Mar; 52(3):268-272. PubMed ID: 28787358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
    Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
    Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.